BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Location
555 Long Wharf Drive, New Haven, CT
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 122 % -48.7%
Quick Ratio 1.92 % -75.2%
Debt-to-equity -139 % +28.3%
Return On Equity 71.8 % -27%
Return On Assets -185 % -76.1%
Operating Margin -6.74K % -100%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.9M shares -48.8%
Common Stock, Shares, Outstanding 20M shares -52.9%
Entity Public Float 41.3M USD -69.4%
Common Stock, Value, Issued 73K USD +73.8%
Weighted Average Number of Shares Outstanding, Basic 14.2M shares +436%
Weighted Average Number of Shares Outstanding, Diluted 14.2M shares +436%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 752K USD -67%
Research and Development Expense 29.5M USD -14.6%
Costs and Expenses 51.4M USD -34.8%
Operating Income (Loss) -50.7M USD +33.9%
Net Income (Loss) Attributable to Parent -68.2M USD +3.92%
Earnings Per Share, Basic -7 USD/shares +93.7%
Earnings Per Share, Diluted -7 USD/shares +93.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.2M USD -10.4%
Inventory, Net 459K USD -69.9%
Other Assets, Current 934K USD -33.2%
Assets, Current 44.4M USD -7.09%
Property, Plant and Equipment, Net 249K USD -54.9%
Operating Lease, Right-of-Use Asset 140K USD -69.6%
Other Assets, Noncurrent 0 USD -100%
Assets 44.8M USD -8.39%
Accounts Payable, Current 16.3M USD +9.32%
Employee-related Liabilities, Current 35K USD -10.3%
Accrued Liabilities, Current 4.36M USD -57.2%
Liabilities, Current 37.8M USD +47.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 134M USD -0.61%
Retained Earnings (Accumulated Deficit) -708M USD -10.7%
Stockholders' Equity Attributable to Parent -88.9M USD -3.84%
Liabilities and Equity 44.8M USD -8.39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12M USD +32%
Net Cash Provided by (Used in) Financing Activities 13.2M USD -50.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 20M shares -52.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.16M USD -87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 37.3M USD -7.59%
Deferred Tax Assets, Valuation Allowance 192M USD +10.6%
Operating Lease, Liability 161K USD -69.6%
Depreciation 303K USD -2.26%
Lessee, Operating Lease, Liability, to be Paid 163K USD -70.4%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 161K USD -56.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 65K USD -83.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -90.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD -83.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 619M USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 600K USD +205%
Share-based Payment Arrangement, Expense 2.12M USD -78.7%
Interest Expense 13.6M USD +17.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%